PROGRAM CHAIR

AJAI CHARI, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, California
PROGRAM OVERVIEW
This enduring program is designed to enhance the knowledge and clinical competence of academic oncology clinicians in the management of relapsed or refractory multiple myeloma. Expert faculty will examine the mechanistic rationale and clinical evidence supporting the use of bispecific antibodies in early relapse, with emphasis on combination strategies to address resistance mechanisms, patient selection, treatment sequencing, and integration of evolving trial data into individualized treatment strategies. Case-based discussions and audience polling will engage learners in applying key concepts to complex clinical scenarios and addressing challenges related to disease biology, prior treatment exposure, and coordination of care between academic and community practice settings.
TARGET AUDIENCE
This educational activity is designed to meet the needs of hematologists/oncologists, oncology nurse practitioners (NPs), and physician assistants (PAs) in academic centers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the MOAs and drug synergies of BsAb combination therapies as well as how they differ from monotherapy and current second line therapies
- Apply clinical trial findings from BsAb combination studies to develop treatment plans for patients with MM
- Integrate strategies to use BsAbs combinations in clinical practice including patient selection and AE management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
AAPA CREDIT DESIGNATION STATEMENT – ENDURING MATERIALS
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/13/27. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Ajai Chari, MD | Consulting fee: AbbVie, AstraZeneca, Bristol Myers Squibb, Candid Therapeutics, Forus Therapeutics, Genentech, Grifols, GSK, Janssen, Legend Biotech, Kite Pharma/Arcellix, Poseida Therapeutics, Regeneron, Sanofi, Takeda Contracted research: Janssen |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Lauren Scott, Medical Director for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Â Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 13, 2026
EXPIRATION DATE: November 13, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR

AJAI CHARI, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, California
SPEAKING FACULTY

ALFRED L. GARFALL, MD, MS
Multiple Myeloma Section Chief, Division of Hematology/Oncology
Department of Medicine
University of Pennsylvania
Associate Professor of Medicine
Perelman School of Medicine & Abramson Cancer Center
Philadelphia, PA
PROGRAM OVERVIEW
This enduring program is designed to enhance the knowledge and clinical competence of community-based oncology clinicians in the management of relapsed or refractory multiple myeloma. Expert faculty will review the latest data on the use of bispecific antibodies in early relapse, with a focus on safety and efficacy, transition of care from tertiary centers, and practical strategies for toxicity management in community oncology practice. Case-based discussions and audience polling will engage learners in applying key concepts to realistic clinical scenarios and addressing common challenges in treatment selection, care coordination, and ongoing disease management.
TARGET AUDIENCE
This educational activity is designed to meet the needs of hematologists/oncologists, oncology nurse practitioners (NPs), and physician assistants (PAs) in community centers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the MOAs and drug synergies of BsAb combination therapies as well as how they differ from monotherapy and current second line therapies
- Apply clinical trial findings from BsAb combination studies to develop treatment plans for patients with MM
- Integrate strategies to use BsAbs combinations in clinical practice including patient selection and AE management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually enduring for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
AAPA CREDIT DESIGNATION STATEMENT – ENDURING MATERIALS
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/13/27. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Ajai Chari, MD | Consulting fee: AbbVie, AstraZeneca, Bristol Myers Squibb, Candid Therapeutics, Forus Therapeutics, Genentech, Grifols, GSK, Janssen, Legend Biotech, Kite Pharma/Arcellix, Poseida Therapeutics, Regeneron, Sanofi, Takeda Contracted research: Janssen |
| Alfred L. Garfall, MD, MS | Consulting Fees: Johnson & Johnson, AstraZeneca, Pfizer, Gracell Biotechnologies, Regeneron, Novartis, GSK Contracted Research: Johnson & Johnson, CRISPR Therapeutics |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Andrew Grzybowski, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, COO of Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Lauren Scott, Medical Director for Med Learning Group, has nothing to disclose.
- Kelly Vicci, RN, BSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Program Manager for Med Learning Group, has nothing to disclose.
- Savannah Barron, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Â Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: November 13, 2026
EXPIRATION DATE: November 13, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.